Express Pharma
JANUARY 18, 2024
Globally, colorectal cancer (CRC) is among the most prevalent and deadly cancers, with a high recurrence rate post-surgery and chemotherapy. Its action post-chemotherapy potentially makes it a pioneering treatment in CRC. This project is a collaborative effort involving several key partners.
Pharmaceutical Business Review
OCTOBER 16, 2023
It recommended approval of KEYTRUDA along with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for locally advanced metastatic HER2-negative gastroesophageal junction (GEJ) adenocarcinoma in adult patients. The latest recommendation is based on data obtained from the Phase III KEYNOTE-859 trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 28, 2022
The approvals include Keytruda plus chemotherapy as neoadjuvant treatment and then continued as a single agent for adjuvant treatment post-surgery in hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. This approval is based on KEYNOTE-564 trial data.
pharmaphorum
OCTOBER 14, 2021
Keytruda (pembrolizumab) can be used in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent or metastatic cervical cancer where the tumour expresses a certain level of PD-L1. 0.77]; p<0.0001) compared to chemotherapy, with or without bevacizumab, where tumours expressed PD-L1 (CPS ?
Pharmaceutical Technology
APRIL 4, 2023
The combination therapy can be used to treat la/mUC patients who do not qualify for cisplatin-containing chemotherapy. KEYTRUDA is an anti-PD-1 therapy developed by Merck, while Padcev has been developed by Astellas and Seagen. Results showed that patients treated with Padcev along with KEYTRUDA achieved a confirmed ORR of 68%.
pharmaphorum
MARCH 2, 2021
Keytruda had been granted accelerated approval in metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. This was based on data from response rate a durability of response rate data from the KEYNOTE-158 and KEYNOTE-028 trial.
European Pharmaceutical Review
JUNE 18, 2024
The US Food and Drug Administration (FDA) has approved the first anti-PD-1 therapy in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. In the placebo plus carboplatin and paclitaxel arm, PFS was 6.5
Expert insights. Personalized for you.
91 
Let's personalize your content